Christopher Plahm's questions to Sanara Medtech Inc (SMTI) leadership • Q3 2024
Question
Christopher Plahm of Tall Pines Capital requested an update on the company's intellectual property progress with Cellerate and the commercial status of the BIASURGE product.
Answer
Executive Ronald Nixon stated that IP progress is a priority, is going very well, and that the company continues to file provisional patents. Executive Seth Yon reported that BIASURGE, which formally launched at the beginning of the year, is on pace with its scaling and facility-level approvals.